Aquestive Therapeutics In... (AQST)
NASDAQ: AQST
· Real-Time Price · USD
2.69
-0.14 (-4.95%)
At close: May 06, 2025, 3:59 PM
2.71
0.74%
Pre-market: May 07, 2025, 08:00 AM EDT
-4.95% (1D)
| Bid | 2.7 |
| Market Cap | 267.17M |
| Revenue (ttm) | 57.56M |
| Net Income (ttm) | -44.14M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -5.27 |
| Forward PE | -4.8 |
| Analyst | Buy |
| Ask | 2.71 |
| Volume | 975,248 |
| Avg. Volume (20D) | 1,567,061 |
| Open | 2.74 |
| Previous Close | 2.83 |
| Day's Range | 2.65 - 2.79 |
| 52-Week Range | 2.20 - 5.80 |
| Beta | 2.02 |
About AQST
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AQST
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Aquestive Therapeutics Inc. is scheduled to release its earnings on May 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+2.2%
Aquestive Therapeutics shares are trading lower af...
Unlock content with
Pro Subscription
4 months ago
+5.2%
Aquestive Therapeutics shares are trading higher after the company announed the FDA has granted seven years of orphan drug exclusivity to Libervant Buccal Film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with epilepsy between two to five years of age.
1 month ago · seekingalpha.com
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyAquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mire...
2 months ago · seekingalpha.com
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call TranscriptAquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...
